- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Bulimia.
Displaying page 1 of 1.
EudraCT Number: 2016-003107-65 | Sponsor Protocol Number: OPNT001-BN-001 | Start Date*: 2017-01-11 | |||||||||||
Sponsor Name:Opiant Pharmaceuticals Inc | |||||||||||||
Full Title: Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa | |||||||||||||
Medical condition: Bulimia nervosa | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006099-38 | Sponsor Protocol Number: P-piller102 | Start Date*: 2012-08-06 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia – A randomized double blinded, placebo controlled study. | ||
Medical condition: Bulimia nervosa is an eating disorder with a prevalence of about 2% in young women (Fairburn and Beglin, 1990). It is characterized by frequent binge eating episodes and the regular use of inapprop... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001490-16 | Sponsor Protocol Number: SCÄ01 | Start Date*: 2017-11-13 |
Sponsor Name:Stockholms läns landsting | ||
Full Title: Lisdexamphetamine treatment of Bulimia Nervosa with and without probable simultaneous Attention Deficit Hyperactivity Disorder (ADHD). A randomized , open, fase II-study with cross-over design. | ||
Medical condition: Bulimia Nervosa with and without simultaneous Attention Deficit Hyperactivity Disorder. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004457-88 | Sponsor Protocol Number: SPD489-346 | Start Date*: 2014-03-05 |
Sponsor Name:Shire Development LLC | ||
Full Title: A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eati... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003313-34 | Sponsor Protocol Number: SPD489-345 | Start Date*: 2013-03-28 |
Sponsor Name:Shire Development LLC | ||
Full Title: A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) IT (Prematurely Ended) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000472-11 | Sponsor Protocol Number: P20-08/BP1.4979 | Start Date*: 2021-11-30 | |||||||||||
Sponsor Name:BIOPROJET PHARMA | |||||||||||||
Full Title: A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder | |||||||||||||
Medical condition: Binge eating disorder (BED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003310-14 | Sponsor Protocol Number: SPD489-344 | Start Date*: 2013-06-18 |
Sponsor Name:Shire Development LLC | ||
Full Title: The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003309-91 | Sponsor Protocol Number: SPD489-343 | Start Date*: 2013-03-20 |
Sponsor Name:Shire Development, LLC | ||
Full Title: The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
